Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis.

Subrata GhoshBrian G FeaganElyssa OttChristopher GasinkBridget GodwinColleen MaranoYe MiaoTony MaEdward V LoftusWilliam J SandbornSilvio DaneseMaria T AbreuBruce E Sands

Published in: Journal of Crohn's & colitis (2024)

The final cumulative ustekinumab safety data through 5 years in CD and 4 years in UC demonstrated favorable safety compared to placebo and continues to support the well-established safety profile across all approved indications.

Keyphrases

ulcerative colitis
randomized controlled trial
clinical trial
machine learning
big data
deep learning
phase iii